Q-omics provides the consensus-scored ZNF491 profile across patient tissues and cancer cell-line models. ZNF491 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF491 is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF491 RNA expression shows 22,046 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, THCA, and GBM as cancer lineages where ZNF491 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF491 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF491 survival associations across molecular data types. ZNF491 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF491 RNA expression–survival associations across cancer types. High ZNF491 expression shows unfavorable associations in LIHC and CESC, but favorable associations in HNSC, BRCA, PAAD and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .007). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF491 RNA expression.
This table summarizes ZNF491 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF491. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF491 shows lower tumor expression in THCA, KICH, COAD and LUSC and higher tumor expression in KIRC and LIHC. The THCA box plot shows higher ZNF491 RNA expression in normal versus tumor tissue (log2 FC = −0.744, t-test p < 0.001).
This table shows molecular features associated with ZNF491 in patient tissues and cancer cell lines. In patient samples, ZNF491 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF491 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
